미국의 반려동물 의료 시장 규모, 점유율, 동향 분석 보고서 : 동물 유형별, 제품별, 유통 채널별, 최종 용도별, 국가별, 부문별 예측(2025-2030년)

U.S. Companion Animal Health Market Growth & Trends:

The U.S. companion animal health market size is estimated to reach at USD 13.97 billion in 2030 and is projected to grow at a CAGR of 9.87% from 2025 to 2030. The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market. According to theNational Pet Owners Survey, 90.5 million families in the U.S. own a pet, out of which 69.0 million own a dog. Moreover, high-income families amounted to approximately 60% of the total spending. In recent years, pet adoption has shown immense growth. This is primarily attributed to the fact that people are healthier and happier in the presence of pets, as found by the Human-Animal Bond Research Initiative Foundation (HABRI).

With the rising adoption of companion animals and growing concerns over their health, there comes a direct association with pet insurance. Presently, pet insurance accounts for a small segment in the insurance industry. The Covid-19 pandemic positively impacted the market growth in the U.S. Key players such as Boehringer Ingelheim Animal Health, Chewy, Elanco, MWI Animal Health, Covetrus, and PetIQ focused on expanding their telemedicine solutions into the market as governments relaxed governance to enable more flexible veterinary examinations during the coronavirus pandemic.

Approval of novel therapeutics and companion animal vaccines continues to present this market with lucrative growth opportunities. Ongoing trends for the adoption of e-commerce, pet insurance, veterinary telemedicine, point of care diagnostic testing, and digitalization of veterinary practices are further accelerated by the crisis of COVID-19.

Groundbreaking technological advances are rapidly transforming the pet health industry. These expansions are maximizing the potential for growth. Companies are taking strategic initiatives in pet health, such as the adoption of big data, wearable technologies to monitor pet health, and the inclusion of stem cell therapy. Moreover, established players are focusing on expanding their portfolios. For instance, Elanco acquired Bayer AG's animal health business unit in August 2019.

The U.S. captured a substantial share of the market. The share attained by this country is primarily a consequence of the presence of prominent market players undertaking extensive expansion strategies. Moreover, the increasing number of R&D investments initiated by the companies is one of the key potential growth factors presumed to be responsible for the sizeable share garnered by the U.S.

U.S. Companion Animal Health Market Report Highlights:

• Based on animal type, the dogs segment led the market with the largest revenue share of 40.57% in 2024 due to the increasing spending on pet care, specifically in developed regions.
• By product, the pharmaceuticals segment is expected to gain popularity in the coming years owing to the growing demand to increase pet longevity and rising R&D activities.
• On the basis of distribution channel, the e-commerce segment is anticipated to witness rapid growth over the forecast period due to the increased convenience offered to pet owners.
• Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 50.68% in 2024. Veterinary hospitals and clinics encourage pet owners to seek out effective treatments by educating them on the value of diagnostics and medication for their pet's health.
• Vetiquinol S.A., Zoetis, Merck, Ceva Sante Animale, Boehringer Ingelheim GmbH, and Elanco are some of the major market participants due to their product offerings and strong regional presence.
• Companies are adopting various strategies to gain competitive advantages, such as new product development, partnerships, mergers and acquisitions, collaborations, and regional expansion.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Health Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of pet diseases
    • 3.2.1.2. Growing uptake of pet insurance
    • 3.2.1.3. Increasing pet population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced treatment
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Companion Animal Health Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Product Pipeline Analysis
  • 3.3.6. Estimated Number of pet popultion in U.S., 2018-2024
  • 3.3.7. COVID-19 Impact Analysis

Chapter 4. U.S. Companion Animal Health Market: Animal type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Companion Animal Health Market: Animal type Movement Analysis & Market Share, 2024 & 2030
• 4.3. Dogs
  • 4.3.1. Dogs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Cats
  • 4.4.1. Cats Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Equine
  • 4.5.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Companion Animal Health Market: Product Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Companion Animal Health Market: Product Movement Analysis & Market Share, 2024 & 2030
• 5.3. Biologics
  • 5.3.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Vaccines
    • 5.3.2.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.2. Modified/ Attenuated Live
      • 5.3.2.2.1. Modified/ Attenuated Live Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.3. Inactivated (Killed)
      • 5.3.2.3.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.4. Other Vaccines
      • 5.3.2.4.1. Other Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Other Biologics
    • 5.3.3.1. Other Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Pharmaceuticals
  • 5.4.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Parasiticides
    • 5.4.2.1. Parasiticides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Anti-infectives
    • 5.4.3.1. Anti-Infectives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Anti-Inflammatory
    • 5.4.4.1. Anti-Inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. Analgesics
    • 5.4.5.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Supplements
  • 5.5.1. Supplements Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Diagnostics
  • 5.6.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Companion Animal Health Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Companion Animal Health Market: Distribution Channel Movement Analysis & Market Share, 2024 & 2030
• 6.3. Retail
  • 6.3.1. Retail Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. E-Commerce
  • 6.4.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Hospital/ Clinic Pharmacies
  • 6.5.1. Hospital/ Clinic Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Companion Animal Health Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Companion Animal Health Market: End Use Movement Analysis & Market Share, 2024 & 2030
• 7.3. Hospitals & Clinics
  • 7.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Point-of-Care
  • 7.4.1. Point-of-Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Position Analysis/ Heap Map Analysis
• 8.3. Company Profiles
  • 8.3.1. Merck & Co., Inc.
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Elanco
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Boehringer Ingelheim GmbH
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Ceva Sante Animale
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Zoetis
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Virbac
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. IDEXX
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Mars Inc.
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Dechra Pharmaceuticals Plc (EQT)
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Vetoquinol S.A.
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives